ICT 기술 융합 허리밴드형 체지방 측정기 개발 및 사업화 방향 제안

김남우 충북대학교 의생명과학경영융합대학원 2016 국내석사

In these days, every people thinks that obesity is no longer personal diet matter but a kind of real disease. As a matter of facts, as obesity is becoming social issues, governmental burden for taking care for obesity is growing rapidly in every countries and people are becoming realize the importance of self-controlling weight and health as well. This research and business plan is aiming at developing new portable body fat analyzer because more and more people are using portable body fat analyzer as controlling body weight by monitoring their weight, especially for body fat rate. There are already many kinds of simple portable body fat analyzers in the market but due to incorrectness & inconsistency data caused by their measuring algorithms and measuring method, they can't get peoples attractions as much as they expected. Nevertheless, lately, those famous companies in body fat analyzer product like Inbody, Korea are developing new innovative portable body fat analyzers which can be used together with smart phone application. In that regards, this developing plan will make a difference with them by focusing our measuring method on abdominal fat which people think the most serious fat matter by designing waist band style measuring device as well as smart phone application for displaying rand monitoring the data. Also, this developing device will target to make a difference with current market simple portable items by making more correct and consistence measuring result nearing to the degree of hospital using high precision body fat measuring machine to make a business success in the market. Through this development and business, following result and synergy can be expected . - Securing different type of technology for portable body fat analyzer - Developing the platform device for adding other bio-signals - Potential success of smart phone application - Influencing financially forward and backward companies related with this business - Developing new technology for small-medium size exporting company Conclusionally, this new development with new technology can help the company's plan to be a representative healthcare based exporting company in these smart healthcare era.

S100A9 및 EGFR에 대한 저해제와 시스플라틴을 유효성분으로 포함하는 근육침윤성 방광암의 치료용 약학적 조성물의 기술사업화 전략

나현수 충북대학교 의생명과학경영융합대학원 2016 국내석사

연구배경 : EGFR의 저해제와 시스플라틴(cisplatin)을 유효성분으로 포함하는 근육 침윤성 방광암의 치료용 약학적 조성물개발에 관한 것이다. 본 기술에 따르면, 근육 침윤성 방광암 환자의 화학요법치료 후의 예후에 대한 정확한 예측이 가능하며, 근육 침윤성 방광암 환자의 화학요법치료를 위한 개인 맞춤형 의의약을 제공함에 있어서 시스플라틴의 민감도에 대한 정보를 제공할 수 있으며, 기존시스플라틴 투여와 병행하여 S100A9과 EGFR의 저해제를 병용 투여함으로써 근육침윤성 방광암 환자의 시스플라틴에 대한 감수성을 증가시킬 수 있다. 이에 근육침윤성 방광암환자에 적용할 수 있는 합제가 필요하며 대상 기업을 선정하고 상기 특허에 대한 특허 분석을 진행하고 기술 가치평가를 진행해 봄으로써 가치를 증명하고 향후 사업화 전략에 대한 고찰이 필요하다. 연구방법 : 방광암 유병률을 조사하고 치료제제 시장분석을 시행하였다. 사업성분석으로 5-force analysis와 SWOT analysis하고 특허분석은 COMPAS분석을 진행하였다. 이후 기술가치 평가를 시행하였다. 연구결과 : 방광암 유병률과 시장분석결과 시장에서 근육침윤성 방광암의 효과적인 치료를 위한 제제가 필요한 상황이다. 국내특허분석결과 경쟁 특허라고 판단하기에 부합되지 않는 낮은 수준의 특허로 경쟁 특허로 분류하기 어려웠다. 국제특허분석결과 주요경쟁자를 대두되는 ,Astellas Pharma Inc의 특허만이 분석한 결과 고형암 및 방광암과 시스플라틴의 상호관계에 대한 내용으로 판명되었다. 사업성 분석을 통하여 의료기관과 신뢰관계를 유지하고 국내외 제약사의 신규 유사 치료제 출시될 수 있으므로 경쟁기술에 대한 대비가 필요함을 파악할 수 있었다. 기술 가치 평가결과 일동제약의 재무제표를 이용한 현금흐름 할인율 평가 878백만원으로 판명되었으며 로열티율 적용 시 8%~15% 내로 추정되며 중간값을 적용하면 105백만원의 가치로 판명되었다. 연구결론 : 국내기업이 성공적으로 국내시장을 확보하고 해외진출을 할 수 있는 방법은 개량 신약에 있다고 판단된다. 상기 특허는 시스플라틴제제와 S100A9, EGFR억제제의 조성물에 대한 특허로 시스플라틴제제는 특허 만료되어 이미 제네릭이 출시되고 있다. EGFR억제제의 경우 2016년 10월 특허 만료를 앞두고 있다. 현재 시스플라틴제제의 제네릭을 보유하고 EGFR억제제 제네릭 출시 계획이 있는 일동제약에 합제 개발을 제안한다. 개발 성공 시 국내 방광암 시장을 기반으로 성장하고 이후 다국적 제약기업을 파트너를 선정하여 성공적인 해외진출을 기대한다. Research background: This study is on the development of pharmacological composition containing inhibitor of EGFR and cisplatin and effective ingredients for the treatment of muscle invasive bladder cancer. According to this technology, it is possible to make accurate forecast on the prognosis following the chemotherapy treatment on the muscle invasive bladder cancer patients and provide information on the sensitivity of cisplatin in provision of medical drugs customized to individuals for the purpose of chemotherapy treatment on muscle invasive bladder cancer patients. Moreover, it is possible to enhance the sensitivity of the muscle invasive bladder cancer patients on cisplatin when S100A9 and inhibitor of EGFR are concurrently administered along with the existing administration of cisplatin. Therefore, composition that can be applied to the muscle invasive bladder cancer patients is necessary as well as to demonstrate its value by selecting the subject company, execute analysis of the aforementioned patent and assessment of technological value. Moreover, consideration on the future commercialization strategy is needed. Methods: Prevalence of bladder cancer is examined along with the analysis of the treatment preparation market. 5-force analysis and SWOT analysis were carried out for the analysis of the business feasibility, and COMPAS analysis was executed to analyze the patent. Assessment of the technological value was executed thereafter. Results: As the result of the analysis of the prevalence of bladder cancer and the market, there is a need for medical drug for effective treatment of muscle invasive bladder cancer in the market. As the result of the analysis of the domestic patent, it was a low level patent that cannot be considered a competing patent and, as such, it was difficult to categorize as a competing patent. As the result of the analysis of the international patent, only the patent of Astella Pharma Inc., which is emerging as the main competitor, has been determined to have contents that indicate the relationship between bladder cancer and cisplatin. Through the analysis of the business feasibility, it was possible to assess that fiduciary relationship with the medical institutions needs to be maintained and preparations for the competing technology are necessary since similar new treatment drug by pharmacologist in Korea and overseas can be launched. As the results of the evaluation of the technological value, it was determined at 878 million Won as the outcome of the evaluation of the primary technological values using the financial statements of Ildong Pharmaceutical. Then, the technological value was determined to be 105 million Won by means of the evaluation of the final technological value by applying the royalty rate. Conclusion: It is determined that improved new medical drug is the method for the domestic company to successfully secure the domestic market and expand into the overseas market. Aforementioned patent is for the composition of cisplatin preparation and S100A9, and EGFR inhibitor. The patent for cisplatin preparation has expired and generic drug has already been launched. In the case of EGFR inhibitor, the patent is due to expire in October 2016. Development of composition is proposed to Ildong Pharmaceutical that currently has the generic product of cisplatin preparation and the plan for launching of the generic product of EGFR inhibitor. In the event of the success of the development, growth on the basis of the domestic bladder cancer is anticipated along with successful expansion into the overseas market by selecting multinational pharmaceutical company as a partner is also anticipated.

새로운 검란 모니터링 개발 및 사업화 제안

장재식 충북대학교 의생명과학경영융합대학원 2016 국내석사

Egg candling is necessary for influenza vaccine manufacturing and poultry. Candling is a method used in embryology to study the growth and development of an embryo inside an egg. The methods use a bright light source behind the egg to show details through the shell and use automated candling machine. Domestic egg blood inspection technology using *VIS/NIR is Neo-eggriser developed by RDA(Rural Development Administration). Wavelength analysis using near-infrared through egg is nondestructive evaluation system for blood in egg and freshness. Furthermore, many companies are manufacturing egg candling machine. For example, E-CAT(Egg Chick Automated Technology), Rame-Hart etc. Devices using NIR for human vein are developed by EVENA MEDICAL and Viewtek etc.. That principal is that hemoglobin absorb NIR. In this study, I developed method that determines live or dead eggs for vaccine manufacturing by using hyperspectral image device and suggested commercialization.

분자진단 기술을 이용한 POCT (Point of Care Testing) Real-time PCR 개발 제안서

김소연 충북대학교 의생명과학경영융합대학원 2016 국내석사

Molecular diagnostic techniques can be applied in medicine treatment and prescription for dose of medicine with the upcoming era of personalized medicine. And its potential value and marketability is expected to be extremely high. The trend of molecular diagnostics is being changed to multi-assay, automation devices of fusion, rapid test, devices of miniaturization, increasing user convenience, and high specificity and sensitivity. These trends are similar to the concept of POCT (Point of Care Testing). Most molecular diagnostic method is PCR-based assay. The strong point of PCR-based assay is easy to combine with other technologies method for rapid test, high efficiency, multi assay and miniaturization of diagnostics devices. PCR-based molecular diagnostics companies in Korea are small in size. and It have limitations in diagnostic techniques, experimental methods, and automation techniques. In addition, domestic hospitals tend to prefer imported molecular diagnostics products due to they discredit domestic products. Therefore, developing competitive molecular diagnostics technologies and commercialization in domestic are needed urgently.